ClinicalTrials.gg
Active, not recruitingNCT05355701Updated Sep 1, 2026

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

A Phase 1 interventional study of PF-07799933 and binimetinib in Melanoma, Non-Small-Cell Lung Cancer and Thyroid Cancer, sponsored by Pfizer. Active, not recruiting at 40 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.

Enrollment
18th of 48
103 · median 77
Started
2022
with 2 others
Phase 1
27 of 52
1 open now
Registered
40th of 52
by date

Among the 52 studies in Melanoma by Pfizer, this one is the 18th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2022, is one of 27 in phase 1, and was the 40th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Melanoma by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.

This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer.

All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine:

  • People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day.
  • People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV).

Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

03

Conditions studied

  • Melanoma
  • Non-Small-Cell Lung Cancer
  • Thyroid Cancer
  • Glioma
  • Advanced Colorectal Cancer (Part 1)
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

This study is seeking participants who meet the following key eligibility criteria:

Inclusion criteria

Inclusion Criteria:

  • Diagnosis of advanced/ solid tumor including primary brain tumor.
  • Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid [DNA], or ctDNA).
  • Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1, Part 2 (doublet), and Part 3 (cohorts 2, 3, 6, 7)).
  • Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies
  • Part 3 (Cohort 1) (BRAF V600 mutant melanoma): Prior BRAF V600 inhibitor therapy required, prior MEK inhibitor therapy required, and therapy required.
  • Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required. No prior BRAF inhibitor/EGFR inhibitor allowed. Participants with MSI-H/dMMR mCRC should receive prior immune checkpoint inhibitor therapy.
  • Part 3 (Cohort 5) (BRAF V600E CRC): No more than 2 cycles of prior 5-FU based chemotherapy allowed. No prior BRAF inhibitor/EGFR inhibitors allowed. Participants with MSI-H/dMMR mCRC should receive prior immune checkpoint inhibitor therapy.

Exclusion criteria

Exclusion Criteria:

  • larger than 4 cm
  • Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO; history of retinal degenerative disease.
  • Concurrent neuromuscular disorder associated with elevated creatine kinase (CK).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Monotherapy dose escalation (Part 1)

    Participants will receive PF-07799933

    Drug: PF-07799933

  • Experimental
    Combination dose escalation (Part 2)

    Participants will receive PF-07799933 in combination with binimetinib or cetuximab

    Drug: PF-07799933 · Drug: binimetinib · Biological: cetuximab

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 1

    Participants will receive PF-07799933

    Drug: PF-07799933

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 2

    Participants will receive PF-07799933

    Drug: PF-07799933 · Drug: binimetinib

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 3

    Participants will receive PF-07799933

    Drug: PF-07799933 · Drug: midazolam

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 4

    Participants will receive PF-07799933 in combination with cetuximab

    Drug: PF-07799933 · Biological: cetuximab

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 5

    Participants will receive PF-07799933 in combination with cetuximab and mFOLFOX6 regimen

    Drug: PF-07799933 · Biological: cetuximab · Drug: fluorouracil · Drug: leucovorin · Drug: oxaliplatin

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 6

    Participants will receive PF-07799933

    Drug: PF-07799933

  • Experimental
    Dose expansion (Part 3) - Tumor and mutation specific Cohort 7

    Participants will receive PF-07799933

    Drug: PF-07799933

Interventions

  • DrugPF-07799933

    Tablet

    Also known as: ARRY-440

  • Tablet

    Also known as: Mektovi, PF-06811462, MEK162

  • Biologicalcetuximab

    Injection for intravenous use

    Also known as: Erbitux

  • syrup

  • Injection for intravenous use

  • Injection for intravenous use

  • Injection for intravenous use

06

What researchers measure

Primary outcomes

  1. Number of participants with dose limiting toxicities (DLTs) (Part 1 and Part 2)

    DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib or cetuximab

    Time frame: Cycle 1 (21 days)

  2. Number of participants with treatment-emergent adverse events (AEs) (Part 1 and Part 2)

    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

    Time frame: Baseline to 28 days after last dose of study medication

  3. Number of participants with clinically significant change from baseline in laboratory abnormalities (Part 1 and Part 2)

    Laboratory abnormalities as characterized by type, frequency, severity, and timing

    Time frame: Baseline to 28 days after last dose of study treatment

  4. Number of participants with clinically significant change from baseline in vital sign abnormalities (Part 1 and Part 2)

    Vital sign abnormalities as characterized by type, frequency, severity, and timing

    Time frame: Baseline to 28 days after last dose of study treatment

  5. Dose interruptions due to AEs (Part 1 and Part 2)

    Incidence of dose interruptions due to AEs

    Time frame: Baseline to 2 years

  6. Dose dose modifications due to AEs (Part 1 and Part 2)

    Incidence of dose modifications due to AEs

    Time frame: Baseline to 2 years

  7. Discontinuations due to AEs (Part 1 and Part 2)

    Incidence of discontinuations due to AEs

    Time frame: Baseline to 2 years

  8. Overall response rate (ORR) (Part 3)

    Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Baseline to 2 years

  9. Number of participants with clinically significant physical exam abnormalities (Part 1 and Part 2)

    Physical exam abnormalities as as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Baseline to 28 days after last dose of study treatment

Secondary outcomes

  1. Part 1 and Part 2: ORR

    ORR as assessed using the RECIST version 1.1.

    Time frame: Baseline to 2 years

  2. Part 1/2/3: Intracranial response

    Intracranial response by RECIST version 1.1 (for brain metastases) \& Response Assessment in Neuro-Oncology (RANO) - for primary brain tumors).

    Time frame: Baseline to 2 years

  3. Part 1 and Part 2: Duration of response

    Duration of response

    Time frame: Baseline to 2 years

  4. Part 3: Number of participants with treatment-emergent adverse events (AEs)

    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

    Time frame: Baseline to 2 years

  5. Part 3: Number of participants with clinically significant change from baseline in laboratory abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity, and timing

    Time frame: Baseline to 2 years

  6. Part 3: Number of participants with clinically significant change from baseline in vital sign abnormalities

    Vital sign abnormalities as characterized by type, frequency, severity, and timing

    Time frame: Baseline to 2 years

  7. Part 3: Dose interruptions due to AEs

    Incidence of dose interruptions due to AEs

    Time frame: Baseline to 2 years

  8. Part 3: Dose dose modifications due to AEs

    Incidence of dose modifications due to AEs

    Time frame: Baseline to 2 years

  9. Part 3: Discontinuations due to AEs

    Incidence of discontinuations due to AEs

    Time frame: Baseline to 2 years

  10. Part 3: Time to event endpoints in each combination

    Time to event endpoints in each combination

    Time frame: Baseline to 2 years

  11. Part 3: Disease Control Rate (DCR)

    DCR

    Time frame: Baseline to 2 years

  12. Part 1/2/3: PK parameters of PF-07799933, Single dose, maximum observed concentration (Cmax)

    PK parameters of PF-07799933, Single dose, Cmax

    Time frame: Baseline to 2 years

  13. Part 1/2/3: PK parameters of PF-07799933, Single dose, time to maximum plasma concentration (Tmax)

    PK parameters of PF-07799933, Single dose, Tmax

    Time frame: Baseline to 2 years

  14. Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast)

    PK parameters of PF-07799933, Single dose, AUClast

    Time frame: Baseline to 2 years

  15. Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 24 hours (AUC24)

    PK parameters of PF-07799933, Single dose, AUC24

    Time frame: Baseline to 2 years

  16. Part 1/2/3: PK parameters of PF-07799933, Single dose, area under plasma concentration-time curve over 48 hours (AUC48)

    PK parameters of PF-07799933, Single dose, AUC48

    Time frame: Baseline to 2 years

  17. Part 1/2/3: PK parameters of PF-07799933, Single dose, terminal elimination half life (t½)

    PK parameters of PF-07799933, Single dose, t½

    Time frame: Baseline to 2 years

  18. Part 1/2/3: PK parameters of PF-07799933, Single dose, area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf)

    PK parameters of PF-07799933, Single dose, AUCinf

    Time frame: Baseline to 2 years

  19. Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent oral clearance (CL/F)

    PK parameters of PF-07799933, Single dose, CL/F

    Time frame: Baseline to 2 years

  20. Part 1/2/3: PK parameters of PF-07799933, Single dose, apparent volume of distribution (Vz/F)

    PK parameters of PF-07799933, Single dose, Vz/F

    Time frame: Baseline to 2 years

  21. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, maximum observed concentration (Cmax)

    PK parameters of PF-07799933, Multiple dose, Cmax

    Time frame: Baseline to 2 years

  22. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, trough plasma or serum concentration (Ctrough)

    PK parameters of PF-07799933, Multiple dose, Ctrough

    Time frame: Baseline to 2 years

  23. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, time to maximum plasma concentration (Tmax)

    PK parameters of PF-07799933, Multiple dose, Tmax

    Time frame: Baseline to 2 years

  24. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, area under the plasma concentration-time curve over the dosing interval (AUCτ)

    PK parameters of PF-07799933, Multiple dose, AUCτ

    Time frame: Baseline to 2 years

  25. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, CL/F

    PK parameters of PF-07799933, Multiple dose, CL/F

    Time frame: Baseline to 2 years

  26. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, average plasma concentration (Cav)

    PK parameters of PF-07799933, Multiple dose, Cav

    Time frame: Baseline to 2 years

  27. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, peak-to-trough ratio (PTR)

    PK parameters of PF-07799933, Multiple dose, PTR

    Time frame: Baseline to 2 years

  28. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, accumulation ratio (Rac)

    PK parameters of PF-07799933, Multiple dose, Rac (AUCτ /AUCsd,τ)

    Time frame: Baseline to 2 years

  29. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, t1/2

    PK parameters of PF-07799933, Multiple dose, t1/2

    Time frame: Baseline to 2 years

  30. Part 1/2/3: PK parameters of PF-07799933, Multiple dose, Vz/F

    PK parameters of PF-07799933, Multiple dose, Vz/F

    Time frame: Baseline to 2 years

  31. Part 3: PK parameters of cytochrome P450 (CYP)3A4 probe substrate midazolam, Cmax

    PK parameters of CYP3A4 probe substrate midazolam, Cmax

    Time frame: Baseline to 2 years

  32. Part 3: PK parameters of CYP3A4 probe substrate midazolam, Tmax

    PK parameters of CYP3A4 probe substrate midazolam, Tmax

    Time frame: Baseline to 2 years

  33. Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUClast

    PK parameters of CYP3A4 probe substrate midazolam, AUClast

    Time frame: Baseline to 2 years

  34. Part 3: PK parameters of CYP3A4 probe substrate midazolam, t½

    PK parameters of CYP3A4 probe substrate midazolam, t½

    Time frame: Baseline to 2 years

  35. Part 3: PK parameters of CYP3A4 probe substrate midazolam, AUCinf

    PK parameters of CYP3A4 probe substrate midazolam, AUCinf

    Time frame: Baseline to 2 years

  36. Part 3: PK parameters of CYP3A4 probe substrate midazolam, CL/F

    PK parameters of CYP3A4 probe substrate midazolam, CL/F

    Time frame: Baseline to 2 years

  37. Part 3: PK parameters of CYP3A4 probe substrate midazolam, Vz/F

    PK parameters of CYP3A4 probe substrate midazolam, Vz/F

    Time frame: Baseline to 2 years

  38. Part 3: TTR

    Time to response (TTR)

    Time frame: Baseline to 2 years

  39. Part 3: DOR

    Duration of response (DOR)

    Time frame: Baseline to 2 years

  40. Part 3: PFS

    Progression-free survival (PFS)

    Time frame: Baseline to 2 years

  41. Part 3: OS

    Overall survival (OS)

    Time frame: Baseline to 2 years

  42. Number of participants with clinically significant physical exam abnormalities (Part 3)

    Physical exam abnormalities as as graded by NCI CTCAE version 5.0

    Time frame: Baseline to 28 days after last dose of study medication

07

Study locations

40 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 61 months after the start.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 61 months is above that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 2, 2022
StartActual
Jul 5, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05355701
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Jul 5, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion